Clinical trials
Acute Leukemia of Ambiguous Lineage clinical trials
Below are recruiting acute leukemia of ambiguous lineage clinical trials, each written for real people, not researchers. We’re tracking 35 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07566377RecruitingPhase 2
Cord Blood Transplant for Children and Young Adults With Blood Cancer
This study tests whether using cord blood stem cells (collected from umbilical cords after birth) can help treat high-risk blood cancers in children and young adults when a matched donor is not quickly available. Cord blood transplants may help prevent cancer from coming back.
New York, New YorkAges Up to 26 years - NCT07495631Recruiting
Chemo + venetoclax + immunotherapy for adult ALL
This trial combines a kid-inspired chemotherapy backbone with a targeted pill (venetoclax) and immunotherapy (special antibodies) to treat adults with Ph-negative acute lymphoblastic leukemia (ALL). The goal is to use a more effective, less toxic approach developed for children.
Tianjin, Tianjin MunicipalityAges 14–60 - NCT06803745Recruiting
Comparing two radiation doses for leukemia transplant
This trial tests whether a lower or higher dose of total body irradiation works better for people with acute leukemia getting a stem cell transplant for the first time. It aims to find the safest and most effective radiation level to prepare your body for the transplant.
Baltimore, MarylandAges Any age - NCT03826992RecruitingPhase 1
Study drug Venetoclax plus Vyxeos for hard-to-treat leukemia
This Phase 1 study tests whether a combination of venetoclax and Vyxeos can treat children and young adults with certain relapsed or treatment-resistant acute leukemias. It may help shrink the leukemia or improve blood counts when standard treatments have not worked.
Cincinnati, OhioAges 1–39 - NCT05660473RecruitingPhase 2
Study of venetoclax plus chemotherapy for Ph-negative ALL
This Phase 2 trial tests whether adding venetoclax to a chemotherapy plan works better for Philadelphia chromosome–negative acute lymphoblastic leukemia (ALL). It may help people achieve deeper remission by targeting leukemia cells in a different way than chemotherapy alone.
TianjinAges 14–60 - NCT06022003RecruitingPhase 2
Azacitidine plus gilteritinib for FLT3-mutated AML
This trial tests whether adding an oral chemotherapy pill (azacitidine) to the targeted drug gilteritinib helps people whose FLT3-mutated AML came back or didn't respond after their first treatment. The goal is to see if the combination is more effective than gilteritinib alone.
AmiensAges 18 years+ - NCT04179929Recruiting
Study for adults with Ph-negative ALL
This trial looks at how to treat a type of leukemia called Ph-negative ALL in adults. It may help people by testing a treatment approach specifically for this leukemia subtype.
Badalona, BarcelonaAges 18–60 - NCT05101551RecruitingPhase 1
Talazoparib with chemotherapy for relapsed childhood AML
This Phase 1 study tests whether talazoparib combined with chemotherapy is safe and potentially effective for children and young adults whose leukemia has come back or did not respond. It focuses on finding the best way to give the treatment and watching for side effects.
Phoenix, ArizonaAges Up to 21 years - NCT05127148Recruiting
Real-world study of pediatric-like treatment for Ph-negative ALL
This study follows how well a “pediatric-style” treatment plan works in teens and young adults with Ph-negative acute lymphoblastic leukemia (ALL) in real-world care. It mainly aims to understand outcomes and safety for patients who fit the specific leukemia and health criteria.
Paraná, Entre Ríos ProvinceAges 18–40 - NCT07695012RecruitingEarly Phase 1
CAR-T cell therapy for B-cell acute lymphoblastic leukemia
This trial tests a personalized cell therapy (CAR-T) for people with B-cell acute lymphoblastic leukemia (ALL) that has come back after treatment or is hard to treat. The therapy uses your own immune cells, modified to find and kill leukemia cells.
RawalpindiAges 5–50 - NCT06481241Recruiting
Chemotherapy plus CAR-T for newly diagnosed Ph- B-ALL
This trial tests giving chemotherapy together with a special immune cell treatment called CAR-T cells for adults who have just been diagnosed with a specific type of leukemia (Ph- B-ALL). The goal is to see if this combination works better than standard treatment.
TianjinAges 18 years+
Hear when a new Acute Leukemia of Ambiguous Lineage trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for acute leukemia of ambiguous lineage?
- Yes. Clin2 currently lists 35 recruiting acute leukemia of ambiguous lineage studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a acute leukemia of ambiguous lineage trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a acute leukemia of ambiguous lineage trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.